Showing results (421-430 of 523) with videos related to

Sort By:
Pageof 53
Journal of the American Academy of Dermatology|October 4, 2016
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasisSteven R Feldman, Diamant Thaçi, Melinda Gooderham, et al.
Dermatology and Therapy|November 22, 2025
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare ProfessionalsRaymond Matthews, April W Armstrong, Matthias Augustin, et al.
Dermatology and Therapy|August 8, 2020
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)Jean-Philippe Lacour, Anthony Bewley, Edward Hammond, et al.
Dermatology and Therapy|December 12, 2022
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)Paolo Gisondi, Alice B Gottlieb, Boni Elewski, et al.
Dermatology and Therapy|July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-AnalysisApril Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 2, 2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque PsoriasisHema N Viswanathan, Alex Mutebi, Cassandra E Milmont, et al.
Oncotarget|June 15, 2018
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physiciansKatharina C Kähler, Christine Blome, Andrea Forschner, et al.
JAMA Dermatology|October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical TrialsMatthias Augustin, Jo Lambert, Carla Zema, et al.
Acta Dermato-Venereologica|July 15, 2021
Patient-Reported Outcome Measures in Dermatology: A Systematic ReviewRachael L Pattinson, Nirohshah Trialonis-Suthakharan, Sunnia Gupta, et al.
Dermatology and Therapy|June 5, 2026
Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and IISteven Daveluy, Alice Bendix Gottlieb, Matthias Augustin, et al.
Pageof 53